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Despite years of intensive investigation that has been made in understanding prostate cancer, it remains a major cause of death
in men worldwide. Prostate cancer emerges from multiple alterations that induce changes in expression patterns of genes and
proteins that function in networks controlling critical cellular events. Based on the exponential aging of the population and the
increasing life expectancy in industrializedWestern countries, prostate cancer in the elderlymen is becoming a disease of increasing
significance. Aging is a progressive degenerative process strictly integrated with inflammation. Several theories have been proposed
that attempt to define the role of chronic inflammation in aging including redox stress, mitochondrial damage, immunosenescence,
and epigenetic modifications. Here, we review the innate and adaptive immune systems and their senescent remodeling in elderly
men with prostate cancer.
1. Introduction
Prostate cancer is the most prevalent malignancy in men
worldwide and is a leading cause of cancer death [1, 2]. Several
men with localized prostate cancer will never suffer any
symptoms or adverse effects of the disease, but because of the
difficulties in identifying this group of patients the majority
receive radical local treatment, which can mainly result in
erectile dysfunction and urinary leakage [3, 4]. The still open
question for clinicians is decidingwhichmenhave “fast grow-
ing” cancers that need essential treatment and which men
have “slow growing” cancers that will never trouble them [5].
Prognostic markers may help to avoid unnecessary treatment
and identify patients with poor outcomes who would be
candidates for trials of adjuvant treatment [6–9]. Based on
the exponential aging of the population and the increasing
life expectancy in industrialized Western countries, prostate
cancer in elderly men is becoming a disease of increasing
significance [10–12].
It has been ascertained that the human prostate is the
site of origin for the two most prevalent diseases of elderly
men: benign prostatic hyperplasia (BPH) and prostate cancer
[13, 14]. Prostate cancer is a highly heterogeneous disease
encompassing a wide variety of pathological entities and
a range of very different clinical behaviors [15]. This is
underpinned at molecular level by a complex array of genetic
alterations that affect cell processes, thus determining the
dynamical progression of the neoplastic disease and its
variable response to treatment (Figure 1) [16, 17]. Genomic
alterations with a potential involvement in prostate cancer
include somatic mutations, gene deletions or amplifica-
tions, and chromosomal rearrangements [17–21]. Epigenetic
changes, more specifically DNA methylation, are the most
common alterations in prostate cancer [22]. These changes
are associated with transcriptional silencing of genes, leading
to an altered cellular behavior. In light of this, epigenetic
markers, especially the glutathione S-transferase pi gene
(GSTP1), have been largely proposed as potential biomarkers
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Figure 1: Multistate prostate carcinogenesis determined by the progression of different qualitative states identifiable in the development
of cancer from normal tissue. The time parameter (𝑡
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) depends on a large number of variables interconnected in many
ways in a nonlinear manner. This makes it extremely difficult to predict the exact time interval between two successive states. Although
carcinogenesis is a continuum, its differentiation into successive states is based on differences in histological and clinical data. Proliferative
inflammatory atrophy (PIA) is a frequently observed lesion in prostate biopsies and some investigators have postulated its involvement
in prostate carcinogenesis. PIA shares genetic alterations with high-grade prostatic intraepithelial neoplasia (HGPIN) and prostate cancer.
HGPIN is currently regarded as the precursor lesion on the basis of pathological, epidemiological, and cytogenetic evidence. HGPIN lesions
can be subdivided into at least four different architectural patterns.
for the evaluation of the probability of biochemical recur-
rence [23]. Other markers have a strong body of scientific
data supporting their role in prostate cancer diagnosis,
most notably adenomatous polyposis coli (APC), retinoic
acid receptor beta (RARB), RAS association domain family
protein 1 (RASSF1), CDH1, CDKN2A (p16), and the O(6)-
methylguanine-DNA methyltransferase (MGMT) [22, 24].
Prostate cancer clinical phenotypes range from indolent or
clinically insignificant to locally aggressive or metastatic [25–
27]. A high number of gene expression profiling studies
have been carried out to attempt the establishment of a
“molecular” staging system, but the identification of genetic
markers that predict aggressive disease has not yet been
clinically demonstrated [28–33].
Molecular associations with prostate cancer phenotypes
continue to be fragmentary and, in some cases, have been
poorly substantiated by follow-up investigations. Histopatho-
logical examination reveals that, like other solid tumors,
prostate cancer is associated with diverse immune cell infil-
trates and that, in the cancer context, epithelial cells coexist
with extracellular matrix components and nonneoplastic cell
types, including fibroblasts and endothelial cells, which col-
lectively form the tumor stroma (Figure 2) [34–36]. Several
lines of evidence support the concept that tumor stromal
cells are not merely a scaffold, but rather they influence
growth, survival, and invasiveness of cancer cells, dynami-
cally contributing to the tumor microenvironment, together
with immune cells [35, 37–40]. It is known that interac-
tions between epithelium and the surrounding stroma are
required to maintain organ function and that these inter-
actions provide proliferative and migratory restraints that
define anatomical and positional information, mediated by
several growth factors and extracellular matrix components
[41]. When cancer develops, transformed cells lose these
constraints while stroma adapts and coevolves to support
the “function” of the tumor [35]. The prostate represents
an example of organ that relies on its surrounding stroma
during normal development and cancer progression [35]. Jia
et al. [42] compared Affymetrix gene expression profiles in
stroma near tumor and identified a set of 115 probe sets for
which the expression levels were significantly correlated with
time-to-relapse.The authors compared patients that relapsed
shortly after prostatectomy (<1 year) and patients that did
not relapse in the first four years after prostatectomy and
identified 131 differentially expressed microarray probe sets
between these two categories. They conclude that tumor-
adjacent prostate cancer stroma contains numerous changes
in gene expression at the time of diagnosis that correlate
with the chance of relapse following prostatectomy [42]. It
is likely that the differences in RNA expression are often
reflected in differences in chromatin modification, DNA
methylation, and protein levels, which could also serve as
stromal markers for progression [43]. Reinertsen et al. [44]
showed that prostate fibroblast primary cultures from areas
with cancer and hyperplasia with PC-3 cells seem tomake the
cancerous and hyperplastic fibroblasts more like each other,
as the number of differentially expressed genes decreases.
The cells of the immune system that are commonly found
infiltrating prostate cancer include IL−17+ macrophages [45,
46], neutrophils [47], mast cells [48], natural killer cells [49],
and cells associated with an adaptive immune response, that
is, T- and B-lymphocytes (Figure 2) [50–54]. Although it is
commonly thought that an immune response localized to
the tumor inhibits cancer growth, it is now clear that some
types of tumor-associated inflammation may also exert an
opposite action, at least at some point of prostate cancer
natural history [55]. Here, we review the innate and adaptive
immune systems and their senescent remodeling in elderly
men with prostate cancer.
2. The Prostate Cancer in the Elderly
Prostate cancer, which is most often diagnosed in men over
the age of 65 years, still remains one of the most common
human cancers [11]. Treatment options vary depending on the
stage and grade of the cancer, as well as patient comorbidity
and age. More than one-half of men aged younger than
65 years are treated with radical prostatectomy [1]. Those
aged 65 years to 74 years commonly undergo radiation
therapy (nearly, 40%). Data show similar survival rates for
patients with early stage disease who are treated with either
of these methods. Active surveillance rather than immediate
treatment is a commonly recommended approach, especially
for older men and those with less aggressive tumors and/or
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Figure 2: Histopathological examination reveals that prostate cancer is associated with diverse immune cell infiltrates and that, in the cancer
context, epithelial cells coexist with extracellular matrix components and nonneoplastic cell types, including fibroblasts and endothelial cells,
which collectively form the tumour stroma. Evidence supports the concept that tumour stromal cells are not merely a scaffold, but rather they
influence growth, survival, and invasiveness of cancer cells, dynamically contributing to the tumour microenvironment. The interactions
between epithelium and the surrounding stroma are required to maintain organ function and provide proliferative and migratory restraints
that define anatomical and positional information, mediated by several growth factors, cytokines, chemokines, and extracellular matrix
components. When cancer develops, transformed cells lose these constraints while stroma adapts and coevolves to support the “function” of
the tumour.
more serious comorbid conditions [1, 56–59]. It is known that
overdiagnosis and overtreatment are frequent in the elderly
men. Competing mortality risks of men older than 75 years
may supersede the risk of dying from prostate cancer several
fold [10].
It is now accepted that aging is associatedwith an increase
in a wide range of age-related diseases, including cardio-
vascular dysfunction, metabolic disorders, neurodegenera-
tion, and cancer [60]. Even in the absence of identifiable
disease, the physiology of organs, tissues, and cells declines
throughout life. Within a tissue, both differentiated cells and
adult stem cells are susceptible to intrinsic and extrinsic
changes during aging [61–64]. In addition to these damages,
cellular aging is also influenced by the exposure to extrinsic
factors, including inflammatory cytokines [65–67]. It has
been accepted that mammalian aging is associated with
molecular, cellular, and physiological changes characterized
by a deteriorating homeostatic balance associated with the
increasing prevalence of neoplasia and other chronic dis-
eases [68]. Although the correlation between inflammatory
pathways and aging is now established, it remains difficult to
demonstrate a causal connection [65]. Several theories have
been proposed to define the role of chronic inflammation in
aging. They include the redox stress, mitochondrial damage,
immunosenescence, endocrinosenescence, epigenetic mod-
ifications, and age-related diseases. Immunosenescence, a
state of gradual deterioration of the immune system brought
on by natural aging, is felt to be a significant contributor
to this increased risk. Careful analyses of healthy people
ranging in age from neonates to centenarians suggest that a
complex and continuous remodeling of the immune system
occurs with age. In particular, deterioration of the immune
system and the endocrine system during aging is thought to
contribute to increased morbidity and mortality. It has been
ascertained that bidirectional interrelations of both sys-
tems are present in the young and in the elderly; that is,
endocrinosenescence modulates the immune system and
immunosenescence changes the endocrine system. Terms
such as alteration, deterioration, and decline do not account
for the complexity of immunosenescence [69]. Hence, the
more appropriate term of “senescent immune remodeling”
has been proposed [70]. It is known that chronic inflamma-
tion might contribute to general aging in several ways. The
perpetual presence of circulating proinflammatory factors
may keep the immune system in a state of “chronic low-level
activation.”This chronic immune activationmight determine
immunosenescence, caused primarily by an exhaustion of
the pool of na¨ıve T-cells, clonal expansion among T- and
B-lymphocytes, and the consequent shrinkage of “immuno-
logical space”; together, these phenomena reduce the body’s
ability to respond to new antigens [71, 72]. In addition to
causing immunosenescence, some proinflammatory factors
(i.e., matrix metalloproteinase-3 (MMP-3)) may degrade
the tissue microenvironment [73]. Several cytokines pro-
duced by senescent cells, including interleukin-6 (IL-6) and
interleukin-8 (IL-8), are known as attractors and activators of
innate immune cells, which can destroy tissue environments
by virtue of the oxidizing molecules they release [74]. It is
now ascertained that immunosenescence leads to increased
incidence of infectious diseases morbidity and mortality as
well as heightened rates of other immune disorders such as
autoimmunity, cancer, and inflammatory conditions [75].
It is known that, after peak reproductive age, the histology
of the prostate begins to undergo age-related changes that
continue throughout life. Additionally, it has been shown
that the size of the prostate typically increases throughout
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a man’s lifetime and that different growth characteristics in
each prostate zonemay contribute to differences in the overall
growth rate with age [76]. Turkbey et al. have recently shown
that magnetic resonance imaging is able to document age-
related changes in prostate zonal volumes [77]. Although
key mechanisms are not yet completely understood, these
changes might be attributed to altered androgen action and
inflammatory processes that lead to either an unabated
trophic effect on the gland and/or a chronic inflammation. It
is possible that repeated epithelial insult sustained through-
out the aging process results in a change of biology from
one of differentiated reproductive function to one of chronic
wound repair. Das et al. [78] have investigated aging-related
changes in important cellular pathways, by systematically
determining the effects of growth and development and aging
on proteomic profiles in different lobes of the rat prostate.
They found that proteins modulated during growth and
development in the dorsolateral (DL) and ventral (VL) lobes
are involved in a variety of biological processes including cell
development, whereas proteinsmodulated during aging were
predominantly related to antioxidant activity and immunity
[78]. Interestingly, the importance of the Golgi apparatus in
cellular activities as a stress sensor, apoptosis trigger, lipid/
protein modifier, mitotic checkpoint, and a mediator of
prostate malignant transformation has been highlighted [79].
Richie et al. [80] compared the levels of selenium, glutathione,
and protein-bound glutathione (GSSP) in blood and prostate
tissues in young (4 months), mature (12 months), old (18
months), and very old (24 months) male F344 rats. They
found that, after 12 months, an 85% reduction in selenium
in the DL was observed, while levels in other lobes were
unchanged. In animals of all ages, levels of glutathione were
the lowest in theVL than in theDL and no significant changes
were observed in glutathione levels by 18 months. However,
GSSP, a marker of oxidative stress, was increased 90% after 18
months in the DL only. These findings of age-related changes
in GSSP and selenium in the DL prostate are consistent with
the sensitivity of this lobe to carcinogenesis and, thus, may
be playing a mechanistic role. It is known that androgens
are involved in every aspect of prostate embryogenesis, and
in aging men with prostatic hyperplasia. Likewise, androgen
deprivation at any phase of life causes a decrease in prostate
cell number and DNA content. The downstream control
mechanisms by which hormonal signals are translated into
differentiation, growth, and prostate function in elderly
men are still unraveled [81, 82]. While many studies have
explored the relationship between prostate cancer and serum
androgens, the association remains ill-defined and clinical
implications are difficult to recognize. Age remains one of
the main factors that complicate the interaction between
prostate malignancy and serum hormone levels, mainly as
testosterone levels begin to decrease in the ageing man
coincidentally as the incidence of prostate cancer starts to
increase. Pierorazio et al. evaluated the relationship between
testosterone levels and the development of high-risk prostate
cancer and found that higher levels of serum free testosterone
are associated with an increased risk of aggressive prostate
cancer among older men [83]. They concluded that higher
levels of serum free testosterone are associated with an
increased risk of aggressive prostate cancer among older men
and that appropriate clinical trials are compulsory to define
the role of testosterone in the development of prostate cancer
and insure the safety of testosterone-replacement therapy
[83].
3. The Innate Immunity and Prostate Cancer
It has been widely demonstrated that the innate immune
system is the first line of defense against infections. Although
it is generally accepted that some aspects of innate immunity
are well preserved in aging, several lines of evidence in
the last decade support the notion that immunosenescence
affects not only adaptive immunity but also innate immunity.
Aside from T- and B-lymphocytes, innate immune cells
orchestrate an inflammatory environment that may function
to either stimulate or inhibit cancer growth. Various innate
immunity cells have been implicated in prostate cancer onset,
progression, and metastasis. Among these, macrophages are
a primary source of secreted proinflammatory cytokines
and are generally distinguished as type 1 (M1) or type
2 (M2) [84, 85]. M1s generally have an interleukin (IL)
12
lowIL-10high phenotype, show impaired expression of reac-
tive nitrogen intermediates and poor antigen presentation,
and have tumoricidal capacity, while they show high expres-
sion of angiogenic factors (including vascular-endothelial
growth factor (VEGF), epidermal-growth factor (EGF), and
semaphorin 4D), MMPs, and cathepsins as well as of the
growth arrest-specific protein GAS6 [86–88]. Additionally,
M1 can support T-helper 1 (Th1) adaptive immunity [89].
Conversely, M2s secrete immunosuppressive cytokines and
promote tumor growth [90]. It has been shown that cancer
cells shape their interaction with macrophages by escaping
phagocytosis and by promoting an M2-like polarization
throughout chemokines and polarizing cytokines including
chemokine ligand 2 (CCL2), colony stimulating factor 1
(CSF1), macrophage slowing factor (MSF), tumor necrosis
factor-alpha (TNF-𝛼), IL-10, and transforming growth factor-
beta (TGF-𝛽). Among the cells with M2 phenotype, the
tumor-associated macrophages (TAMs) have been shown to
be capable of secreting proteases that enhance invasion and
metastases, together with a range of cytokines inhibiting an
adaptive tumor-specific immune response, and angiogenic
factors that increase neovascularity. It has been ascertained
that phagocytosis is also unimpaired in the elderly [91].
Although macrophages are usually found located around
necrotic areas of tumor and the advancing tumor margin,
their role in prostate cancer still remains controversial.While
it was originally thought that the main function of TAMs
was direct cytotoxic effects on tumoral cells, phagocytosis
apoptotic/necrotic cell debris, and present tumor-associated
antigens to T-lymphocytes, current evidence suggests that
inflammation and TAMs can also promote tumor growth
and metastasis. The density, size, and location of tumor
infiltratingmacrophages in prostate cancer have been showed
as powerful predictors of patient outcome, and prostate
cancer specimens’ harbor increased positive cells express-
ing the macrophage specific marker CD68 compared to
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benign glands [92–94]. Additionally, it was demonstrated
that expression of macrophage colony-stimulating factor
(M-CSF) and its receptor colony-stimulating factor-1 recep-
tor (CSF-1R) are increased in primary tumors of patients
exhibiting metastatic disease [95]. Shirotake et al. showed
that both high monocyte chemoattractant protein-1 (MCP-
1) expression and high macrophage infiltration in prostate
cancer specimens correlate with a high prostate-specific
antigen (PSA) recurrence rate and that AT1R blockade (ARB)
inhibits MCP-1 expression through the PI3K/Akt pathway
and blocks macrophage infiltration in castration-resistant
prostate cancer [96]. Nonomura et al. [97] found that TAM
infiltration was significantly correlated with serum PSA
level, Gleason score, and clinical stage. Shimura et al. [98]
demonstrated the association between TAM infiltration and
disease-free survival after radical prostatectomy. They also
examined the association between TAM infiltration and the
rate of detection of prostate cancer at a repeat biopsy of the
prostate in patients in whom the first biopsy was negative.
They found no difference in TAM count between the cases
with or without prostate cancer. By contrast, the macrophage
scavenger receptor- (MSR-) positive inflammatory cells count
in patients with cancer was significantly lower than that in
patients without cancer at the repeat biopsy. Logistic regres-
sion analysis indicated that the MSR count at first biopsy
is a significantly better predictive factor for positive repeat
biopsy than PSA velocity, interval between first and repeat
biopsies, or TAM count. Decreased infiltration of MSR-posi-
tive inflammatory cells in negative first biopsy specimens
was correlated with positive findings in the repeat biopsy.
MSR count has been, therefore, proposed as a valid index to
avoid unnecessary repeat biopsies [97]. Gollapudi et al. [99]
have recently shown that mean TAM number was higher in
cancer cores versus prostatic intraepithelial neoplasia (PIN)
and benign tissue and higher in high-grade prostate cancer
supporting the potential role of TAMs in prostate cancer
development. In a study comprising 38 prostate cancers, the
presence of CD1a+ Langerhans cells was associated mainly
with low-grade prostate carcinoma. Liu et al. [54] found a
significant correlation between low numbers of CD1a+ cells
and a high Gleason score and pathological stage pT3. The
numbers of CD1a+ cells were, however, very low in normal
and benign prostate tissues [54]. Other studies have, however,
demonstrated variable evidence for TAMs during prostate
cancer progression.
4. The Adaptive Immunity in Prostate Cancer
Ageing is accompanied by alterations to T-lymphocyte
immunity and also by a low-grade chronic inflammatory state
termed “inflammaging.” Immune cell infiltrate is a constant
feature in normal prostate, BPH, and prostatic cancer [100].
It has been stated that the aged T-cell response is character-
ized by increased production of proinflammatory cytokines,
which could significantly contribute to prostate carcino-
genesis through induction of key inflammation-mediated
prosurvival factors [101, 102]. Hussein et al. investigated the
cells of the immune system present in normal prostate,
BPH, and prostatic cancer [103]. It has been observed that
PIA lesions are associated with chronic inflammation of
the prostate, and histological transitions have been noted
between areas of PIA and high-grade prostate intraepithelial
neoplasia (HGPIN) and between PIA and prostate cancer
[104]. The inflammatory infiltrates are mainly represented by
CD3+ T-lymphocytes (70–80%, mostly CD4+ lymphocytes)
and CD19+ or CD20+ B-lymphocytes (nearly, 10–15%) [105].
In the normal prostate, the infiltrates around the periglan-
dular area are mainly composed of T-lymphocytes (70%
CD8+ cells), while lymphoid aggregates are located in the
fibromuscular stroma. These aggregates, mainly consisting
of B-lymphocytes follicles surrounded by parafollicular T-
lymphocytes with CD4+ cells, are two times more frequent
than CD8+ cells. In the adult prostate, a different inflam-
matory infiltrate pattern has been described in relation
to the type and extension of inflammation. Robert et al.
[106] showed that, in 282 patients with BPH, there was an
inflammatory infiltrate constituted by T-lymphocytes (i.e.,
CD3+ cells) in the 80% of cases associated with 52% of
antigen-presenting cells, including B-lymphocytes (CD20+
cells). In contrast, a significant decrease in the counts of these
cells was observed in high-grade prostatic cancer compared
to BPH [105]. The increased density of CD3+ T-lymphocytes
in BPH suggests that the initial response to cellular damage is
mediated by cell-mediated immunity. The decreased density
of immune cells in high-grade prostatic cancer may reflect
immunosuppression. Recently, Fujii et al. found no signifi-
cant difference in the number of infiltrating T-lymphocytes
between benign andmalignant tumors; however, the number
of infiltrating B-lymphocytes was significantly reduced in
malignant glands [107].
5. The Antigen-Presenting Machinery in
Prostate Cancer
Defects in HLA class I antigen-processing machinery (APM)
component expression often have a negative impact on the
clinical course of tumors and on the response to T-cell-based
immunotherapy [108]. Aged neutrophils are also less able
to respond to rescue from apoptosis, while aged dendritic
cells (DCs) are less able to stimulate T- and B-lymphocytes
[109]. The altered T-lymphocyte stimulation is a result of
changes in human leukocyte antigen expression and cytokine
production, and lower B-lymphocyte stimulation is a result
of changes in DCs immune complex binding [109]. It is
known that DCs are the most potent, professional antigen-
presenting cells of the immune system [110].With their ability
to interact with B- and T-lymphocytes and their widespread
localization, they are a pivotal component of the innate
immune system. The recently described positive outcome of
a clinical trial with T-lymphocyte-based immunotherapy in
prostate cancer has stimulated interest in the characterization
of the APM component expression in prostate cancer lesions,
since this “machinery” plays a crucial role in the generation
and expression of the trimeric HLA class I surface antigen
complex on tumor cells. Immunohistochemical staining of
a tissue microarray including 59 primary prostate cancers
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lesions and matched normal tissues has shown downregu-
lation of all the HLA class I APM components analyzed,
although with a different frequency in tumor lesions when
compared to normal prostate tissues [108]. A primary finding
was the frequent loss or downregulation of calnexin and/or
tapasin, which appears to be an independent prognostic
marker of tumor recurrence. In contrast, HLA class I HC
expression levels were less affected in primary prostate
cancers; the frequency of downregulation described byBlades
et al. has been found markedly lower than that reported
by other authors [111] in a large number of prostate cancer
lesions and that reported in other tumor types. In contrast,
high frequencies of loss or downregulation of low molecular
weight polypeptides 2 (LMP2), transporters associated with
antigen processing 1 (TAP1), and tapasin as well as of 𝛽2-
microglobulin were demonstrated in prostate cancer when
compared to normal prostate tissue. The frequency of LMP2,
TAP1, and tapasin downregulation is higher than that found
in lung, colorectal, hepatocellular, cervical, and renal cell
carcinoma. In parallel to the findings in head and neck
squamous cell carcinoma, cervical carcinoma, esophageal
carcinoma, breast carcinoma, and melanoma, the impaired
TAP expression in prostate cancer lesions is associated with
tumor grading, staging, and time to recurrence. Qiu et al.
found that, in vitro, the prostate cancer cell PC-3 infectedwith
Lentivirus TAP1 can efficiently overexpress TAP1 and tapasin,
andHLA-1 was also upregulated on the surface of the infected
cells. The Lentivirus TAP1 infection increased the apoptosis
rate of PC-3 cells. In addition, with the coculture PC-3 cells
and lymphocytes, TAP1 augmented the expression of CD3+
CD8+ CD38+ cells [112].
6. Immunotherapy and Prostate Cancer
The goals of any cancer therapy are to improve disease
control, palliate pain, and overall survival [113]. In 2010, the
American Food and Drug Administration (FDA) approved
the first therapeutic cancer vaccine, called sipuleucel-T, for
the treatment of castration refractory prostate cancer [114,
115]. Different from the currently adopted chemotherapy
drugs that produce widespread cytotoxicity to kill tumor
cells, anticancer vaccines and immunotherapies focus on
empowering the immune system to overcome the tumor. It
has been shown that prostate cancer is an idealmodel for can-
cer vaccine development. This is mainly due to its humoral
and cellular immunity to a range of cancer antigens, which
are good candidates for vaccine therapy to generate a robust
antitumor response. Recently, Cheema et al. suggested the
potential application of BORIS (i.e., a cancer-testis antigen
normally present at high levels in the testis and aberrantly
expressed in various tumors and cancer cell lines) as a
biomarker for prostate cancer diagnosis, an immunotherapy
target, and, potentially, a prognostic marker of aggressive
prostate cancer [116]. The ability of BORIS to activate the
androgen receptor gene suggests its involvement in the
growth and development of prostate cancer [116]. Chiriva-
Internati et al. first reported the aberrant expression of the
cancer-testis antigen A-kinase anchor protein-4 (AKAP-4)
in prostate cancer, which will potentially be developed as
a biomarker in prostate cancer. They also provide evidence
that AKAP-4 is a potential target for prostate cancer adoptive
immunotherapy or antitumor vaccination [117]. Beginning
in the early 1990s, several tumor-associated antigen genes
including the cancer-testis antigens were identified that
exhibited tumor-specific expression. The cancer-testis anti-
gens are a group of proteins that are typically restricted to
the testis in the normal adult but are aberrantly expressed
in cancers of unrelated histologic origin [118]. Hudolin et al.
observed MAGE-A1 in 10.8% of carcinoma samples, whereas
multi-MAGE-A and NY-ESO-1/LAGE-1 stained 85.9% and
84.8% of samples using immunohistochemistry, suggesting
that a panel of CT antigens rather than individual onesmay be
more valuable as biomarkers [119]. Smith et al. suggested that
multiple synovial sarcoma X chromosome breakpoint (SSX)
proteins are expressed in metastatic prostate cancers, which
are amenable to simultaneous targeting [120].
Enzalutamide (i.e., a second-generation androgen antag-
onist) has been recently approved for castration-resistant
prostate cancer treatment. Ardiani et al. showed that enza-
lutamidemediated immunogenicmodulation in TRAMP-C2
cells. In vivo, enzalutamide mediated reduced genitourinary
tissueweight, enlargement of the thymus, and increased levels
of T-cell excision circles. Because no changes were seen in T-
lymphocytes function, as determined byCD4+ T-lymphocyte
proliferation and Treg functional assays, enzalutamide was
determined to be immune inactive [121]. The combination
of enzalutamide and immunotherapy has been, therefore,
suggested as a promising treatment strategy for castration-
resistant prostate cancer. A renewed interest in prostatic
acid phosphatase (i.e., a nonspecific phosphomonoesterase
synthesized in prostate epithelial cells, whose level pro-
portionally increases with prostate cancer progression) has
been shown, because of its usefulness in prognosticating
intermediate to high-risk prostate cancers and its success
in the immunotherapy of prostate cancer [122]. Based on
the good prognostic value of prostatic acid phosphatase and
the potential usefulness of prostatic acid phosphatase as an
antigen, an immunotherapy employing autologous prostatic
acid phosphatase-loaded dendritic cells was initiated [123].
Wada et al. used a well-described genetically engineered
mouse, autochronous prostate cancer model to explore
the relative sequencing and dosing of anti-cytotoxic T-
lymphocyte-associated antigen-4 (CTLA-4) antibody when
combinedwith a cell-based, granulocytemacrophage colony-
stimulating factor- (GM-CSF-) secreting vaccine [124].These
experiments corroborate recent clinical data, which suggest
that the combination of CTLA-4 blockade and cell-based,
GM-CSF-secreting vaccines may have significant antitumor
effects in men with prostate cancer. These data also indicate
that the “therapeutic window” of such an approach may
be maximized through meticulous study of various dosing
regimens. Additionally, future clinical studies may find that
the addition of cyclophosphamide to this treatment strategy
allows for reduction in the dose of anti-CTLA-4, potentially
limiting autoimmune toxicity. In a recent phase I trial, Perez
et al. demonstrated that the AE37 vaccine is safe and induces
HER-2/neu-specific immunity in a heterogeneous population
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of HER-2/neu+ prostate cancer patients [125]. Clusterin is
a cytoprotective chaperone protein that is overexpressed
in many tumor types and is upregulated in response to
cellular stress caused by cancer treatments, including hor-
monalmanipulation, radiation, and chemotherapy. Custirsen
is known as a second-generation antisense oligonucleotide
that is complementary to clusterin mRNA and potently
suppresses clusterin expression in preclinical models of
prostate cancer as well as in clinical trials. The innova-
tive first-in-human phase I neoadjuvant trial demonstrated
dose-dependent plasma and prostate tissue concentrations
of custirsen, which was well tolerated at all dose levels
[126]. Results from the clinical trials (i.e., sipuleucel-T-
based vaccine, GVAX-prostate cancer, viral prostate cancer
vaccines, DNA-based vaccines, and gene-mediated cytotoxic
immunotherapy) indicate that prostate cancer vaccines are
generally safe and, encouragingly, capable of generating
tumor-specific T-lymphocyte responses. It is becoming evi-
dent that prostate cancer patients with early-stage disease
may be those who obtain the main benefits from vaccines.
7. Concluding Remarks
The primary risk for prostate cancer is aging, often associ-
ated with inflammation (Figure 2). Inflammation results in
a tissue microenvironment that alters the normal prostate
epithelial cell differentiation program and that accelerates the
initiation of prostate cancer with a basal cell origin [127].
Despite the continuous progress, prostate cancer is one of
the main cancers that affect men, especially older men. This
is largely due to the fact that the tumoral mass cannot be
identified using current imaging techniques. Prostate cancer
can only be diagnosed on the basis of increased PSA levels
associated with a low accuracy of the biopsy fragments and
the well-known subjectivity of a pathologist’s interpretation.
This has led tomany patients being overtreated, undertreated,
or simply inappropriately treated and allowed the progression
of the disease. Prostate cancer in the aging male will become
an increasingly important and controversial health care issue.
Because the median age of diagnosis for men with prostate
cancer is greater than 75 years, prostate cancer can be
considered a disease of the elderly. The aging population
and lowering PSA threshold to 2.6 ng/mL will have the most
significant impact on estimated new prostate cancer cases in
2021 [128]. Several disease-specific factors (i.e., stage, tumor
grade, and PSA level) and patient-specific factors (i.e., age,
comorbidity, and functional status) need to be considered
in the decision-making process [129]. Rice et al. evaluated
the outcomes between a variety of treatments for low-risk
prostate cancer in patients of 70 years of age and older
[130]. They found that patients managed on watchful waiting
without secondary treatment had the poorest overall survival
and that watchful waiting without secondary treatment rep-
resents a statistically significant predictor of overall mortality
[130]. Specific to prostate cancer, it has been identified that
macrophage interactions with tumor cells promote androgen
resistance and increased prostate cancer invasion through
tissue factor expression [12, 37]. In vivo studies by Parrinello
et al. showed a significant increase in infiltrating inflamma-
tory cells includingmacrophages in the prostates of agedmice
[38], reflecting the prominent role for immune cells during
the aging process, which is linked to prostate cancer develop-
ment. Identifying contributing factors in the tumor microen-
vironment, which modulate this cleavage event on tumor
cells, is necessary for determining alternative therapeutic
targets for a multimodality approach to inhibit the invasion
steps of metastasis. Despite the technical advantages offered
by robotic systems and other techniques, the diagnostic pro-
cess requires further improvement. It is known that prostate
cancer consists of distinct subpopulations of cancer cells, each
with its own characteristic sensitivity to a given therapeutic
agent. Cancer therapies can be seen as filters that remove the
sensitive subpopulations but allow insensitive subpopulations
to escape. The combined efforts of urologists, pathologists,
gerontologists, and biologists can contribute much towards
improving our understanding of the complexity of prostate
cancer, and such a multidisciplinary approach will help to
clarify existing concepts, categorize current knowledge, and
suggest alternative approaches to the discovery of biomarkers
and predictive values that urgently need to be translated into
clinical practice.
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